Semaglutide vs Liraglutide vs Tirzepatide: Head-to-Head Weight Loss Comparison
Comparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weight loss, followed by semaglutide, then liraglutide, with varying side effect profiles.
Quick Facts
What This Study Found
Comparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weight loss, followed by semaglutide, then liraglutide, with varying side effect profiles.
Key Numbers
74.6% of Kuwaiti adults are classified as overweight or obese. Survey conducted February–May 2024 comparing three GLP-1 drugs.
How They Did This
Clinical or preclinical study with methodology detailed in the full publication.
Why This Research Matters
This finding has implications for the millions of patients using or considering peptide-based therapies.
The Bigger Picture
This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.
What This Study Doesn't Tell Us
Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.
Questions This Raises
- ?What are the long-term implications of these findings?
- ?How do these results compare to other studies in this area?
- ?What further research is needed to confirm and extend these findings?
Trust & Context
- Key Stat:
- Key finding Comparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weig
- Evidence Grade:
- Evidence grade assessment based on study design and methodology detailed in the full publication.
- Study Age:
- Published in 2025. Reflects current state of peptide therapeutic research.
- Original Title:
- A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.
- Published In:
- Frontiers in nutrition, 12, 1590379 (2025)
- Authors:
- Alali, Saleh, Al-Otaibi, Wed, Ashodian, Karen, Achour, Nour, Almulla, Aishah, Mutlaq, Hessa
- Database ID:
- RPEP-09835
Evidence Hierarchy
Frequently Asked Questions
What does this study mean for patients?
Comparison of three leading GLP-1/GIP drugs for weight loss found tirzepatide produced the most weight loss, followed by semaglutide, then liraglutide, with varying side effect profiles.
How reliable are these findings?
The evidence level depends on study design. Clinical trials provide stronger evidence than case reports. Consult the full publication and discuss with your healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09835APA
Alali, Saleh; Al-Otaibi, Wed; Ashodian, Karen; Achour, Nour; Almulla, Aishah; Mutlaq, Hessa. (2025). A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.. Frontiers in nutrition, 12, 1590379. https://doi.org/10.3389/fnut.2025.1590379
MLA
Alali, Saleh, et al. "A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait.." Frontiers in nutrition, 2025. https://doi.org/10.3389/fnut.2025.1590379
RethinkPeptides
RethinkPeptides Research Database. "A comparison of Glucagon-like peptide-1 receptor agonists on..." RPEP-09835. Retrieved from https://rethinkpeptides.com/research/alali-2025-a-comparison-of-glucagonlike
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.